Phase 3 Recruiting NIH
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in Pennsylvania: - Pennsylvania Hospital — Philadelphia, Pennsylvania
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Penn State Children's Hospital — Hershey, Pennsylvania
- Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in Pennsylvania: - Geisinger Medical Center — Danville, Pennsylvania
- Penn State Children's Hospital — Hershey, Pennsylvania
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
Phase 3 Recruiting Network
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…
Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Penn State Children's Hospital — Hershey, Pennsylvania
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
Phase 3 Recruiting Network
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in Pennsylvania: - Saint Vincent Hospital — Erie, Pennsylvania
- Jefferson Hospital — Jefferson Hills, Pennsylvania
- Forbes Hospital — Monroeville, Pennsylvania
- Allegheny Valley Hospital — Natrona Heights, Pennsylvania
- University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…
Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in Pennsylvania: - Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Paoli Memorial Hospital — Paoli, Pennsylvania
- Lankenau Medical Center — Wynnewood, Pennsylvania
Phase 3 Recruiting Industry
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Sponsor: Polaris Group
NCT ID: NCT05712694
Sites in Pennsylvania: - UPenn (Abramson Cancer Center, Pennsylvania Hospital) — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Indepe…
Sponsor: PharmaMar
NCT ID: NCT06088290
Sites in Pennsylvania: - University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride…
Sponsor: Advenchen Laboratories, LLC
NCT ID: NCT03016819
Sites in Pennsylvania: - Thomas Jefferson Hospital - Sidney Kimmel Cancer Center — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Pennsylvania: - Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134) — Lancaster, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Pennsylvania: - Local Institution - 2108 — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Pennsylvania: - University of Pennsylvania (U Penn) — Philadelphia, Pennsylvania
- University Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people wi…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05634369
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \…
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06541262
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center and Children's Hospital — Hershey, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Pennsylvania: - Local Institution - 2114 — Hershey, Pennsylvania
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Pennsylvania: - Children's Hospital of Philadelphia (CHOP) ( Site 1021) — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants wi…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05734066
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 2 Recruiting NIH
This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type of cancer.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05333458
Sites in Pennsylvania: - University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Phase 2 Recruiting Network
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sponsor: AIDS Malignancy Consortium
NCT ID: NCT04305691
Sites in Pennsylvania: - Abramson Cancer Center at Pennsylvania Hospital — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any …
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06465199
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center and Children's Hospital — Hershey, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Sponsor: USWM CT, LLC
NCT ID: NCT05642455
Sites in Pennsylvania: - Children's Hospital of Philedephia — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). The phase 2 primary objective is to estim…
Sponsor: Theodore Laetsch
NCT ID: NCT06721689
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT04796012
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05918640
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania